Reported 0 shares, down 18,975 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 37000 |
| 2022-03-31 | 35000 |
| 2022-06-30 | 0 |
| 2024-12-31 | 874618 |
| 2025-03-31 | 65534 |
| 2025-06-30 | 42170 |
| 2025-09-30 | 52712 |
| 2025-12-31 | 766299 |
| 2026-03-31 | 1241000 |
| 2026-06-30 | 403217 |
| 2026-09-30 | 283921 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Unchanged | 478,142 | 0 (0.0%) | 0.03% | $283,921 | 2026-11-16 | |
| Q2 2026 | Reduced | 478,142 | -200,000 (-29.5%) | 0.04% | $403,217 | 2026-08-14 | |
| Q1 2026 | Unchanged | 678,142 | 0 (0.0%) | 0.1% | $1,241,000 | 2026-05-15 | |
| Q4 2025 | Added | 678,142 | +649,649 (2280.0%) | 0.06% | $766,299 | 2026-02-18 | |
| Q3 2025 | Unchanged | 28,493 | 0 (0.0%) | < 0.01% | $52,712 | 2025-11-14 | |
| Q2 2025 | Unchanged | 28,493 | 0 (0.0%) | < 0.01% | $42,170 | 2025-08-14 | |
| Q1 2025 | Reduced | 28,493 | -70,000 (-71.1%) | < 0.01% | $65,534 | 2025-05-15 | |
| Q4 2024 | New | 98,493 | +98,493 (0.0%) | 0.12% | $874,618 | 2025-02-14 | |
| Q2 2022 | Reduced | 0 | -18,975 (-100.0%) | 0 | $0 | 2022-08-12 | |
| Q1 2022 | Added | 18,975 | +3,912 (26.0%) | < 0.01% | $35,000 | 2022-05-13 | |
| Q4 2021 | Unchanged | 15,063 | 0 (0.0%) | < 0.01% | $37,000 | 2022-02-14 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
36 managers reported ONCONOVA THERAPEUTICS INC COM for Q2 2022.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | Added | 511,993 | +28,369 | < 0.01% | $676,000 | 5 qtrs |
| RENAISSANCE TECHNOLOGIES LLC | Added | 333,323 | +11,580 | < 0.01% | $440,000 | 3 qtrs |
| BlackRock Inc | Unchanged | 248,881 | 0 | < 0.01% | $329,000 | 5 qtrs |
| TWO SIGMA ADVISERS LP | Reduced | 178,912 | -173,400 | < 0.01% | $236,000 | 5 qtrs |
| GEODE CAPITAL MANAGEMENT LLC | Added | 169,847 | +6,878 | < 0.01% | $224,000 | 5 qtrs |
| MILLENNIUM MANAGEMENT LLC | Added | 61,390 | +37,275 | < 0.01% | $81,000 | 3 qtrs |
| CITADEL ADVISORS LLC | New | 59,512 | +59,512 | < 0.01% | $79,000 | 4 qtrs |
| STATE STREET CORPORATION | Added | 52,790 | +2,400 | < 0.01% | $70,000 | 5 qtrs |
| Beacon Pointe Advisors LLC | Added | 51,976 | +5,949 | < 0.01% | $68,000 | 5 qtrs |
| NORTHERN TRUST CORPORATION | Unchanged | 30,783 | 0 | < 0.01% | $41,000 | 5 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2022
- Filed
- August 12, 2022
- Filing type
- 13F-HR
- Position type
- COM NEW
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.